cover image - Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants - Elsevier eBook on VitalSource, 3rd Edition
ISBN: 9780323936804
Copyright: 2026
Publication Date: 01-21-2025
Page Count: 936
Imprint: Elsevier
List Price: $121.99

Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants - Elsevier eBook on VitalSource, 3rd Edition

by Laura D. Rosenthal, DNP, RN, ACNP-BC, FAANP and Jacqueline Rosenjack Burchum, DNSc, FNP-BC, CNE

Elsevier eBook on VitalSource

cover image - Lehne’s Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants - Elsevier eBook on VitalSource, 3rd Edition
ISBN: 9780323936804
Copyright: 2026
Publication Date: 01-21-2025
Page Count: 936
Imprint: Elsevier
List Price: $121.99
Was $121.99

Now $107.35

Or $0.00 with a valid access code
**American Journal of Nursing (AJN) Book of the Year Awards, 2nd Place in Advanced Practice Nursing, 2025**
**Selected for 2025 Doody’s Core Titles® with "Essential Purchase" designation in Advanced Practice**

Lehne's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants, Third Edition builds on the same foundation of clearly explained, up-to-date, and clinically current content as Lehne’s trusted undergraduate text, while focusing on the information that advanced practice nurses and Physician Assistants specifically need for safe and effective prescribing. Introductory chapters provide foundational content in the areas of prescriptive authority, rational drug selection, prescription writing, and promoting positive outcomes of drug therapy. Core drug chapters focus on the drugs that you will most commonly see in clinical practice. Pharmacotherapeutic decision-making is emphasized, with Black Box Warnings and new Drug Decision Guide boxes. This edition features completely updated content with new chapters on drugs for sexual dysfunction and drugs for transgender health. It’s everything you need to be a safe and effective prescriber!
    • UPDATED! Content throughout reflects the latest drug information and evidence-based treatment guidelines and protocols
    • NEW! Drugs for Sexual Dysfunction and Drugs for Transgender Health chapters in a newly combined Reproductive Health unit promote health equity
    • NEW! Drug Decision Guide boxes for selected drugs emphasize a rational process for drug selection
    • NEW! Clinical Pearls boxes highlight expert tips for rational drug prescription
    • NEW! Chapter-opening Evolve links and “Top 300” drug icons throughout identify drugs that appear on the Top 300 prescribed drug list to help you focus your study time
    • ENHANCED! Introductory chapters emphasize prescriber-level pharmacokinetics and pharmacodynamics content
    • NEW! Coverage addresses immunizations and therapeutics (e.g., Regeneron, Resdemivir, dexamethasone) for SARS-CoV-2 infection (COVID-19)
    • UPDATED! Enhanced coverage of sexually transmitted infections reflects the latest evidence-based guidelines
    • NEW! Drug content addresses medications for ectoparasite infestations
    • Introductory chapters tailored to the specific needs of beginning prescribers cover topics such as prescriptive authority, rational drug selection and prescription writing, and promoting positive outcomes of drug therapy
    • Carefully focused pharmacotherapeutics content reflects the drugs most commonly seen and used by primary and acute care prescribers, with an emphasis not on the first drug discovered or developed in each drug class, but on the agents most often used today
    • Chapters address primary care drugs first, as appropriate, followed by acute care drugs
    • Prescriber-focused pedagogical aids further reinforce the most important information for prescribers
    • UNIQUE! Summary of Key Prescribing Considerations at the end of each drug chapter provides a concise summary of essential prescriber information
    • Coverage of interprofessional collaboration addresses the growing global emphasis on interprofessional collaboration and incorporates opportunities for interprofessional collaborative practice throughout
    • Integrated coverage of Canadian trade names appears throughout and is highlighted with a familiar maple-leaf icon
  • UNIT I Introduction
    1. Prescriptive Authority
    2. Rational Drug Selection and Prescription Writing
    3. Promoting Positive Outcomes of Drug Therapy

    UNIT II Basic Principles of Pharmacology
    4. Pharmacokinetics, Pharmacodynamics, and Drug Interactions
    5. Adverse Drug Reactions and Medication Errors
    6. Individual Variation in Drug Responses
    7. Genetic and Genomic Considerations in Pharmacotherapeutics

    UNIT III Drug Therapy Across the Life Span
    8. Drug Therapy During Pregnancy and Breastfeeding
    9. Drug Therapy in Pediatric Patients
    10. Drug Therapy in Geriatric Patients

    UNIT IV Peripheral Nervous System Drugs
    11. Basic Principles of Neuropharmacology
    12. Physiology of the Peripheral Nervous System
    13. Muscarinic Agonists and Cholinesterase Inhibitors
    14. Muscarinic Antagonists
    15. Adrenergic Agonists
    16. Adrenergic Antagonists
    17. Indirect-Acting Antiadrenergic Agents

    UNIT V Central Nervous System Drugs
    18. Introduction to Central Nervous System Pharmacology
    19. Drugs for Parkinson Disease
    20. Drugs for Alzheimer Disease
    21. Drugs for Seizure Disorders
    22. Drugs for Muscle Spasm and Spasticity

    UNIT VI Drugs for Pain
    23. Local Anesthetics
    24. Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics
    25. Drugs for Headache

    UNIT VII Psychotherapeutic Drugs
    26. Antipsychotic Agents and Their Use in Schizophrenia
    27. Antidepressants
    28. Drugs for Bipolar Disorder
    29. Sedative-Hypnotic Drugs
    30. Management of Anxiety Disorders
    31. Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder

    UNIT VIII Substance Use Disorders
    32. Substance Use Disorders I: Basic Considerations
    33. Substance Use Disorders II: Alcohol
    34. Substance Use Disorders III: Nicotine and Smoking
    35. Substance Use Disorders IV: Major Drugs of Misuse Other Than Alcohol and Nicotine

    UNIT IX Drugs That Affect the Heart, Blood Vessels, Blood, and Blood Volume
    36. Review of Hemodynamics
    37. Diuretics
    38. Drugs Acting on the Renin-Angiotensin-Aldosterone System
    39. Calcium Channel Blockers
    40. Vasodilators
    41. Drugs for Hypertension
    42. Drugs for Heart Failure
    43. Antidysrhythmic Drugs
    44. Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels
    45. Drugs for Angina Pectoris
    46. Anticoagulant and Antiplatelet Drugs
    47. Drugs for Deficiency Anemias

    UNIT X Drugs for Endocrine Disorders
    48. Drugs for Diabetes
    49. Drugs for Thyroid Disorders

    UNIT XI Reproductive Health
    50. Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications
    51. Birth Control
    52. Androgens
    53. Drugs for Benign Prostatic Hyperplasia
    54. Drugs for Sexual Dysfunction
    55. Transgender Health

    UNIT XII Antiinflammatory, Antiallergic, and Immunologic Drugs
    56. Review of the Immune System
    57. Childhood Immunization
    58. Antihistamines
    59. Cyclooxygenase Inhibitors, Nonsteroidal Antiinflammatory Drugs, and Acetaminophen
    60. Glucocorticoids in Nonendocrine Disorders

    UNIT XIII Drugs for Bone and Joint Disorders
    61. Drug Therapy for Rheumatoid Arthritis
    62. Drug Therapy for Gout
    63. Drugs Affecting Calcium Levels and Bone Mineralization

    UNIT XIV Respiratory Tract Drugs
    64. Drugs for Asthma and Chronic Obstructive Pulmonary Disease
    65. Drugs for Allergic Rhinitis, Cough, and Colds

    UNIT XV Gastrointestinal Drugs
    66. Drugs for Peptic Ulcer Disease
    67. Laxatives
    68. Other Gastrointestinal Drugs

    UNIT XVI Nutrition and Complementary Therapies
    69. Vitamins
    70. Drugs for Obesity
    71. Complementary and Alternative Therapy

    UNIT XVII Therapy for Infectious and Parasitic Diseases
    72. Basic Principles of Antimicrobial Therapy
    73. Drugs That Weaken the Bacterial Cell Wall I: Penicillins
    74. Drugs That Weaken the Bacterial Cell Wall II: Other Drugs
    75. Bacteriostatic Inhibitors of Protein Synthesis
    76. Aminoglycosides: Bactericidal Inhibitors of Protein Synthesis
    77. Sulfonamide Antibiotics and Trimethoprim
    78. Drug Therapy for Urinary Tract Infections
    79. Drug Therapy for Tuberculosis
    80. Miscellaneous Antibacterial Drugs
    81. Antifungal Agents
    82. Antiviral Agents I: Drugs for Non-HIV Viral Infections
    83. Antiviral Agents II: Drugs for HIV Infection
    84. Drug Therapy for Sexually Transmitted Infections
    85. Anthelmintics

    UNIT XVIII Cancer Therapy
    86. Introduction to Immunomodulators
    87. Supportive Care of Patients Receiving Anticancer Drugs
    88. Drugs for Cancer Pain

    UNIT XIX Drugs for Eyes, Ears, and Skin
    89. Drugs for Disorders of the Eye
    90. Drugs for Disorders of the Skin
    91. Drugs for Disorders of the Ear

    UNIT XX Drug Therapy in Acute Care
    92. Agents Affecting the Volume and Ion Content of Body Fluids
    93. Management of ST-Elevation Myocardial Infarction
    94. Drugs for Acute Care

    Appendix: Canadian Drug Information
  • Laura D. Rosenthal, DNP, RN, ACNP-BC, FAANP, Professor, College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA and Jacqueline Rosenjack Burchum, DNSc, FNP-BC, CNE, Associate Professor, College of Nursing, Department of Advanced Practice and Doctoral Studies, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • Ways of Reading
      • The appearance of the text and page layout can be modified according to the capabilities of the reading system (font family and font size, spaces between paragraphs, sentences, words, and letters, as well as color of background and text)
      • This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation
      • All content can be read as read aloud speech or dynamic braille
      • Has alternative text descriptions for images
    • Conformance
    • Navigation
      • Table of contents to all chapters of the text via links
      • Index with links to referenced entries
      • Elements such as headings, tables, etc. for structured navigation
      • Page list to go to pages from the print source version
    • Rich Content
      • Math formulas in accessible format (MathML)
      • Information-rich images are described by extended descriptions
    • Hazards
      • The publication contains no hazards
    • Product Content
      • The primary content is text.
      • Content includes a significant number of actionable (clickable) web links to external content, downloadable resources, supplementary material, etc.
      • Content includes a significant number of actionable (clickable) cross-references, hyperlinked notes and annotations, or with other actionable links between largely textual elements (e.g., quiz/test questions, 'choose your own ending', etc.).
      • Content includes additional textual content such as an interview, feature article, essay, bibliography, quiz/test, other background material, or text that is not included in a primary or 'unenhanced' version.
      • Content includes supplementary text as promotional content such as, for example, a teaser chapter.
      • Content includes photographs, whether in a plate section / insert or not.
      • Content includes figures, diagrams, charts and/or graphs, including other 'mechanical' (i.e. non-photographic) illustrations.
      • Content includes images displayed in a specific order for the purpose of graphic storytelling or giving information (e.g. graphic novels, comics and manga). May include text integrated into the image (as speech and thought bubbles, textual 'sound' effects, captions etc.).
      • Content includes text within images, including text-as-text embedded in diagrams, charts, or within images containing speech balloons, thought bubbles, captions, etc.
      • Content includes visual content that is purely decorative and is not necessary to understanding of the content.
      • Content includes mathematical notations, formulae.
      • At least some text - including text within other images - is 'text as an image' (i.e., a picture of text).
    • Legal Considerations
      • No information is available
    • Additional Accessibility Information
      • Content is enhanced with ARIA roles to optimize organization and facilitate navigation
      • Page breaks included from the original print source
      • For readers with color vision deficiency, use of color (e.g., in diagrams, graphics and charts, in prompts, or on buttons inviting a response) is not the sole means of graphical distinction or of conveying information
      • The body text is presented with a contrast ratio of at least 4.5:1 (or 3:1 for large/heading text)
      • Ultra-high contrast between text and background
      • E-publication includes basic navigation (usually less detailed than TOC-based navigation)
      • Where links, controls or buttons are included in the content, the purpose or functionality of each link, control or button is apparent from the associated text alone - or where it is unclear, separate link, control or button descriptions are provided
      • All (or substantially all) textual matter is arranged in a single logical reading order (including text that is visually presented as separate from the main text flow, e.g., in boxouts, captions, tables, footnotes, endnotes, citations, etc.). Non-textual content is also linked from within this logical reading order. (Purely decorative non-text content can be ignored).
      • Content provides explanations for unusual words, abbreviations, acronyms, idioms, jargon in an accessible form, such as glossaries, scripted pop-ups.
      • Where interactive content is included in the product, controls are provided (e.g., for speed, pause and resume, reset) and labelled to make their use clear.
      • The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.
Was $121.99

Now $107.35

Or $0.00 with a valid access code